Last reviewed 2026-06-10 · How we verify

Short-term relief of symptoms of anxiety — Treatment Landscape & Competitive Intelligence

Short-term relief of symptoms of anxiety (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

Marketed treatment landscape

Approved drugs treating Short-term relief of symptoms of anxiety, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

1. The University of Hong Kong · 1 drug in Short-term relief of symptoms of anxiety

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Short-term relief of symptoms of anxiety:

• Short-term relief of symptoms of anxiety treatment updates — RSS
• Short-term relief of symptoms of anxiety treatment updates — Atom
• Short-term relief of symptoms of anxiety treatment updates — JSON

Cite this brief

Drug Landscape (2026). Short-term relief of symptoms of anxiety — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/short-term-relief-of-symptoms-of-anxiety. Accessed 2026-06-10.

Related

• Short-term relief of symptoms of anxiety full disease profile — treatment pathway, diagnostics, guidelines
• Browse all CI briefs
• Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing